2026-08-07First statedRevisions to earnings forecasts
「In addition to strong sales of hematology instruments in the Americas during the first quarter, the yen has remained weaker than assumed against other currencies. Accordingly, we have revised our consolidated earnings forecasts for the six months ending September 2026 and the full fiscal year ending March 2027, as revenue, operating profit, profit before tax, interim profit attributable to owners of the parent and profit for the year are all expected to exceed the previous forecasts.」
The forecast for the six months ending September 2026 was revised upward to revenue of ¥265,000 million and operating profit of ¥25,000 million, while the full-year forecast was revised upward to revenue of ¥545,000 million and operating profit of ¥60,000 million.